[Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD].
Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines. This present article describes the severity classification and the pharmacological treatment of stable COPD. GesEPOC identifies four clinical phenotypes with differential treatment: non-exacerbator, mixed COPD-asthma, exacerbator with emphysema and exacerbator with chronic bronchitis. Pharmacological treatment of COPD is based on bronchodilation in addition to other drugs depending on the clinical phenotype and severity. Severity is established by the BODE/BODEx multidimensional scales. Severity can also be approximated by assessing airflow obstruction, dyspnea, level of physical activity and history of exacerbations. GesEPOC is a new, more individualized approach to COPD treatment according to the clinical characteristics of the patients.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona, Spain. marcm@separ.es
Marc
M
Miravitlles
Juan José
JJ
Soler-Cataluña
Myriam
M
Calle
Jesús
J
Molina
Pere
P
Almagro
José Antonio
JA
Quintano
Juan Antonio
JA
Riesco
Juan Antonio
JA
Trigueros
Pascual
P
Piñera
Adolfo
A
Simón
José Luis
JL
López-Campos
Joan B
JB
Soriano
Julio
J
Ancochea
D000465:Algorithms; D001993:Bronchodilator Agents / Q000627:therapeutic use; D006801:Humans; D010641:Phenotype; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D012720:Severity of Illness Index
D001993:Bronchodilator Agents